Teva claims success in celiac study; BioMarin, Ascendis settle patent dispute

Data ReadoutpositivePositive

AI Analysis

Summary

Teva reported positive results from a celiac disease study with potential pipeline-in-a-product opportunities, while BioMarin and Ascendis settled a patent dispute. GSK advanced a competitor to Moderna's flu shot as a high-stakes trial was paused.

Clinical Trial Data

Outcome Details

Teva claims success in celiac study

Importance:5/10

Sentiment:

0.60

clinical_trialpatent_settlementceliac_diseaseflu_vaccinepipeline

Related Companies

$TEVA $BMRN $ASND

Read the original article

Published by BioPharma Dive on September 2, 2026 2:12 PM

Read Original